Interleukin-6 and risk of colorectal cancer

results from the CLUE II cohort and a meta-analysis of prospective studies

Artemisia Kakourou, Charalampia Koutsioumpa, David Lopez, Judith Hoffman-Bolton, Gary Bradwin, Nader Rifai, Kathy J. Helzlsouer, Elizabeth A. Platz, Konstantinos K. Tsilidis

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: The association between prediagnostic interleukin-6 (IL-6) concentrations and risk of colorectal cancer was evaluated in a nested case–control study and a meta-analysis of prospective studies. Methods: Colorectal cancer cases (n = 173) and matched controls (n = 345) were identified between 1989 and 2000 among participants in the CLUE II cohort of Washington Country, Maryland. Matched odds ratios and the corresponding 95 % confidence intervals (CIs) were estimated using conditional logistic regression models. Results: Participants in the highest third of plasma IL-6 concentration had a 2.48 times higher risk of colon cancer compared to participants in the bottom third (95 % CI 1.26–4.87; p-trend 0.02) after multivariate adjustment. This association did not differ according to the stage of disease, age, sex, or other potential modifying variables and remained statistically significant after adjustment for C-reactive protein concentrations. No statistically significant association was observed for rectal cancer risk. The meta-analysis of six prospective studies yielded an increased but borderline statistically significant risk of colon cancer per 1 U increase in naturally logarithm-transformed IL-6 (summary RR 1.22; 95 % CI 1.00–1.49; I 2 46 %). An inverse association was noted for rectal cancer (RR 0.69; 95 % CI 0.54–0.88; I 2 0 %), but there was evidence for small-study effects (p 0.02). Conclusion: Our findings provide support for a modest positive association between IL-6 concentrations and colon cancer risk. More work is needed to determine whether IL-6 is a valid marker of colorectal inflammation and whether such inflammation contributes to colon and rectal cancer risk.

Original languageEnglish (US)
Pages (from-to)1449-1460
Number of pages12
JournalCancer Causes and Control
Volume26
Issue number10
DOIs
StatePublished - Oct 14 2015
Externally publishedYes

Fingerprint

Meta-Analysis
Colorectal Neoplasms
Interleukin-6
Prospective Studies
Colonic Neoplasms
Rectal Neoplasms
Confidence Intervals
Logistic Models
Inflammation
C-Reactive Protein
Odds Ratio

Keywords

  • Cohort study
  • Colorectal cancer
  • Inflammation
  • Meta-analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Interleukin-6 and risk of colorectal cancer : results from the CLUE II cohort and a meta-analysis of prospective studies. / Kakourou, Artemisia; Koutsioumpa, Charalampia; Lopez, David; Hoffman-Bolton, Judith; Bradwin, Gary; Rifai, Nader; Helzlsouer, Kathy J.; Platz, Elizabeth A.; Tsilidis, Konstantinos K.

In: Cancer Causes and Control, Vol. 26, No. 10, 14.10.2015, p. 1449-1460.

Research output: Contribution to journalArticle

Kakourou, A, Koutsioumpa, C, Lopez, D, Hoffman-Bolton, J, Bradwin, G, Rifai, N, Helzlsouer, KJ, Platz, EA & Tsilidis, KK 2015, 'Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies', Cancer Causes and Control, vol. 26, no. 10, pp. 1449-1460. https://doi.org/10.1007/s10552-015-0641-1
Kakourou, Artemisia ; Koutsioumpa, Charalampia ; Lopez, David ; Hoffman-Bolton, Judith ; Bradwin, Gary ; Rifai, Nader ; Helzlsouer, Kathy J. ; Platz, Elizabeth A. ; Tsilidis, Konstantinos K. / Interleukin-6 and risk of colorectal cancer : results from the CLUE II cohort and a meta-analysis of prospective studies. In: Cancer Causes and Control. 2015 ; Vol. 26, No. 10. pp. 1449-1460.
@article{f96ac11b75d04dbe84fbed084f2c15ad,
title = "Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies",
abstract = "Purpose: The association between prediagnostic interleukin-6 (IL-6) concentrations and risk of colorectal cancer was evaluated in a nested case–control study and a meta-analysis of prospective studies. Methods: Colorectal cancer cases (n = 173) and matched controls (n = 345) were identified between 1989 and 2000 among participants in the CLUE II cohort of Washington Country, Maryland. Matched odds ratios and the corresponding 95 {\%} confidence intervals (CIs) were estimated using conditional logistic regression models. Results: Participants in the highest third of plasma IL-6 concentration had a 2.48 times higher risk of colon cancer compared to participants in the bottom third (95 {\%} CI 1.26–4.87; p-trend 0.02) after multivariate adjustment. This association did not differ according to the stage of disease, age, sex, or other potential modifying variables and remained statistically significant after adjustment for C-reactive protein concentrations. No statistically significant association was observed for rectal cancer risk. The meta-analysis of six prospective studies yielded an increased but borderline statistically significant risk of colon cancer per 1 U increase in naturally logarithm-transformed IL-6 (summary RR 1.22; 95 {\%} CI 1.00–1.49; I 2 46 {\%}). An inverse association was noted for rectal cancer (RR 0.69; 95 {\%} CI 0.54–0.88; I 2 0 {\%}), but there was evidence for small-study effects (p 0.02). Conclusion: Our findings provide support for a modest positive association between IL-6 concentrations and colon cancer risk. More work is needed to determine whether IL-6 is a valid marker of colorectal inflammation and whether such inflammation contributes to colon and rectal cancer risk.",
keywords = "Cohort study, Colorectal cancer, Inflammation, Meta-analysis",
author = "Artemisia Kakourou and Charalampia Koutsioumpa and David Lopez and Judith Hoffman-Bolton and Gary Bradwin and Nader Rifai and Helzlsouer, {Kathy J.} and Platz, {Elizabeth A.} and Tsilidis, {Konstantinos K.}",
year = "2015",
month = "10",
day = "14",
doi = "10.1007/s10552-015-0641-1",
language = "English (US)",
volume = "26",
pages = "1449--1460",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "10",

}

TY - JOUR

T1 - Interleukin-6 and risk of colorectal cancer

T2 - results from the CLUE II cohort and a meta-analysis of prospective studies

AU - Kakourou, Artemisia

AU - Koutsioumpa, Charalampia

AU - Lopez, David

AU - Hoffman-Bolton, Judith

AU - Bradwin, Gary

AU - Rifai, Nader

AU - Helzlsouer, Kathy J.

AU - Platz, Elizabeth A.

AU - Tsilidis, Konstantinos K.

PY - 2015/10/14

Y1 - 2015/10/14

N2 - Purpose: The association between prediagnostic interleukin-6 (IL-6) concentrations and risk of colorectal cancer was evaluated in a nested case–control study and a meta-analysis of prospective studies. Methods: Colorectal cancer cases (n = 173) and matched controls (n = 345) were identified between 1989 and 2000 among participants in the CLUE II cohort of Washington Country, Maryland. Matched odds ratios and the corresponding 95 % confidence intervals (CIs) were estimated using conditional logistic regression models. Results: Participants in the highest third of plasma IL-6 concentration had a 2.48 times higher risk of colon cancer compared to participants in the bottom third (95 % CI 1.26–4.87; p-trend 0.02) after multivariate adjustment. This association did not differ according to the stage of disease, age, sex, or other potential modifying variables and remained statistically significant after adjustment for C-reactive protein concentrations. No statistically significant association was observed for rectal cancer risk. The meta-analysis of six prospective studies yielded an increased but borderline statistically significant risk of colon cancer per 1 U increase in naturally logarithm-transformed IL-6 (summary RR 1.22; 95 % CI 1.00–1.49; I 2 46 %). An inverse association was noted for rectal cancer (RR 0.69; 95 % CI 0.54–0.88; I 2 0 %), but there was evidence for small-study effects (p 0.02). Conclusion: Our findings provide support for a modest positive association between IL-6 concentrations and colon cancer risk. More work is needed to determine whether IL-6 is a valid marker of colorectal inflammation and whether such inflammation contributes to colon and rectal cancer risk.

AB - Purpose: The association between prediagnostic interleukin-6 (IL-6) concentrations and risk of colorectal cancer was evaluated in a nested case–control study and a meta-analysis of prospective studies. Methods: Colorectal cancer cases (n = 173) and matched controls (n = 345) were identified between 1989 and 2000 among participants in the CLUE II cohort of Washington Country, Maryland. Matched odds ratios and the corresponding 95 % confidence intervals (CIs) were estimated using conditional logistic regression models. Results: Participants in the highest third of plasma IL-6 concentration had a 2.48 times higher risk of colon cancer compared to participants in the bottom third (95 % CI 1.26–4.87; p-trend 0.02) after multivariate adjustment. This association did not differ according to the stage of disease, age, sex, or other potential modifying variables and remained statistically significant after adjustment for C-reactive protein concentrations. No statistically significant association was observed for rectal cancer risk. The meta-analysis of six prospective studies yielded an increased but borderline statistically significant risk of colon cancer per 1 U increase in naturally logarithm-transformed IL-6 (summary RR 1.22; 95 % CI 1.00–1.49; I 2 46 %). An inverse association was noted for rectal cancer (RR 0.69; 95 % CI 0.54–0.88; I 2 0 %), but there was evidence for small-study effects (p 0.02). Conclusion: Our findings provide support for a modest positive association between IL-6 concentrations and colon cancer risk. More work is needed to determine whether IL-6 is a valid marker of colorectal inflammation and whether such inflammation contributes to colon and rectal cancer risk.

KW - Cohort study

KW - Colorectal cancer

KW - Inflammation

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=84941425687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941425687&partnerID=8YFLogxK

U2 - 10.1007/s10552-015-0641-1

DO - 10.1007/s10552-015-0641-1

M3 - Article

VL - 26

SP - 1449

EP - 1460

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 10

ER -